References
1. Hodkinson B., Tikly M., Adebajo A. Rheumatoid arthritis in the developing world: stepping up to the challenge. Clin. Rheumatol. 2014; 33 (9): 1195–6. DOI: 10.1007/s10067-014-2690-3.
2. Radner H., Lesperance T., Accortt N., Solomon D. Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res (Hoboken). 2017; 69 (10): 1510–8. DOI: 10.1002/acr.23171.
3. Nasonov E.L., Karateev D.E., Satybaldyev A.M. Rheumatoid arthritis in Russian Federation according to the Russian register of patients with arthritis (message I). Nauchno-prakticheskaya revmatologiya. 2015; 5: 472–84. DOI: 10.14412/1995-4484-2016-50-62. (in Russian)
4. Mulumba C., Lebughe P., Mbuyi-Muamba J.-M., Makulo J.-R., Lepira F., Mukaya J., et al. Prevalence and associated factors of subclinical atherosclerosis in rheumatoid arthritis at the university hospital of Kinshasa. BMC Rheum. 2019; 3: 37. DOI: 10.1186/s41927-019-0085-4.
5. Avina-Zubieta J.A., Thomas J., Sadatsafavi M., Lehman A.J., Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann. Rheum. Dis. 2012; 71 (9): 1524–9. DOI: 10.1136/annrheumdis-2011-200726.
6. Garza-García C., Rocio S.S., Orea-Tejeda A., Castillo-Martínez L., Eduardo C., López-Campos J.L., et al. Risk factors for asymptomatic ventricular dysfunction in rheumatoid arthritis patients. ISRN Cardiol. 2013;2013: 635439. DOI: 10.1155/2013/635439.
7. Jagpal A., Navarro-Millán I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheum. 2018; 2: 10. DOI: 10.1186/s41927-018-0014-y.
8. Skeoch S., Bruce I.N. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat. Rev. Rheumatol. 2015; 11 (7): 390–400. DOI: 10.1038/nrrheum.2015.40.
9. Sarli B., Baktir A.O., Cebicci M., Dogan Y., Demirbas M., Kurtul S., et al. Predictors of endothelial dysfunction in patients with rheumatoid arthritis. Angiology. 2014; 65 (9): 778–82. DOI: 10.1177/0003319713504485.
10. Moraga A., Lao K.H., Zeng L. Angiogenesis and Cardiovascular Diseases: The Emerging Role of HDACs, Physiologic and Pathologic Angiogenesis – Signaling Mechanisms and Targeted Therapy. Dan Simionescu and Agneta Simionescu. IntechOpen. 2017. DOI: 10.5772/66409. URL: https://www.intechopen.com/books/physiologic-and-pathologic-angiogenesis-signaling-mechanisms-and-targeted-therapy/angiogenesis-and-cardiovascular-diseases-the-emerging-role-of-hdacs.
11. Paradowska-Gorycka A., Pawlik A., Romanowska-Prochnicka K., Haladyj E., Malinowski D., Stypinska B., et al. Relationship between VEGF gene polymorphisms and serum VEGF protein levels in patients with rheumatoid arthritis. PLoS One. 2016; 11 (8): e0160769. DOI: 10.1371/journal. pone.0160769.
12. Elshabrawy H.A., Chen Z., Volin M.V., Ravella S., Virupannavar S. , Shahrara S. The pathogenic role of angiogenesis in rheumatoid arthritis. Review Paper. Angiogenesis. 2015; 18: 433–48. DOI: 10.1007/s10456-015-9477-2.
13. Gogiraju R., Bochenek M.L., Schäfer K. Angiogenic endothelial cell signaling in cardiac hypertrophy and heart failure. Review article. Front. Cardiovasc. Med. 2019; 6: 20. DOI: 10.3389/fcvm.2019.00020.
14. Azizi G., Boghozian R., Mirshafiey A. The potential role of angiogenic factors in rheumatoid arthritis. Int. J. Rheum. Dis. 2014; 17: 369–83. URL: https://onlinelibrary.wiley.com/doi/pdf/10.1111/1756-185X.12280.
15. Gluzman-Poltorak Z., Cohen T., Shibuya M., Neufeld G. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J. Biol. Chem. 2001; 276 (22): 18 688–94. DOI: 10.1074/jbc.M006909200.
16. Tsai Y.C., Fotinou C., Rana R., Yelland T., Frankel P., Zachary I., et al. Structural studies of neuropilin-2 reveal a zinc ion binding site remote from the vascular endothelial growth factor binding pocket. FEBS J. 2016; 283 (10): 1921–34. DOI: 10.1111/febs.13711.
17. De Rosa L., Di Stasi R., D’Andrea L.D. Pro-angiogenic peptides in biomedicine. Arch. Biochem. Biophys. 2018; 660 (15): 72–86. DOI: 10.1016/j.abb.2018.10.010.
18. Cardoso J.V., Machado D.E., Ferrari R., Silva M.C., Berardo P.T., Perini J.A. Polymorphisms in VEGF and KDR genes in the development of endometriosis: a systematic review. Rev. Bras. Saude Mater. Infant. 2016; 16 (3): 219–32. DOI: 10.1590/1806-93042016000300002.
19. Yap R.W. K., Lin M.H., Shidoji Y., Yap W.S. Association of stress, mental health, and VEGFR-2 gene polymorphisms with cardiometabolic risk in Chinese Malaysian adults. Nutrients. 2019; 11 (5): 1140. DOI: 10.3390/nu11051140.
20. Li L., Pan Y., Dai L., Liu B., Zhang D. Association of genetic polymorphisms on vascular endothelial growth factor and its receptor genes with susceptibility to coronary heart disease. Med. Sci. Monit. 2016; 22: 31–40. DOI: 10.12659/MSM.895163.
21. Luo Y., Luo J., Peng H. Associations between genetic polymorphisms in the VEGFA, ACE, and SOD2 genes and susceptibility to diabetic nephropathy in the Han Chinese. Genet. Test Mol. Biomarkers. 2019; 23 (9): 644–51. DOI: 10.1089/gtmb.2018.0320.
22. Szekanecz Z., Koch A.E. Vascular involvement in rheumatic diseases. Arthritis Res. Ther. 2008; 10 (5): 224. DOI: 10.1186/ar2515.
23. Vorlova S., Rocco G., LeFave C.V., Jodelka F.M., Hess K., Hastings M.L., et al. Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. Mol. Cell. 2011; 43: 927–39. DOI: 10.1016/j.molcel.2011.08.009.
24. Vaz-Drago R., Custódio N., Carmo-Fonseca M. Deep intronic mutations and human disease. Hum. Genet. 2017; 136 (9): 1093–111. DOI: 10.1007/s00439-017-1809-4.
25. Abramowicz A., Gos M. Splicing mutations in human genetic disorders: examples, detection, and confirmation. J. Appl. Genet. 2018; 59: 253–68. DOI: 10.1007/s13353-018-0444-7.
26. Zhao X., Meng L., Jiang J., Wu X. Vascular endothelial growth factor gene polymorphisms and coronary heart disease: a systematic review and meta-analysis. Growth Factors. 2018; 36 (3–4): 153–63. DOI: 10.1080/08977194.2018.1477141.
27. Ma W., Wang Y., Han X., Zhu Y., Liu N.-F. Association of genetic polymorphisms in vascular endothelial growth factor with susceptibility to coronary artery disease: a meta-analysis. BMC Med. Genet. 2018; 19: 108. DOI: 10.1186/s12881-018-0628-3.
28. Wang Y., Zheng Y., Zhang W., Yu H., Lou K., Zhang Y., et al. Polymorphisms of KDR gene are associated with coronary heart disease. J. Am. Coll. Cardiol. 2007; 50 (8): 760–7. DOI: 10.1016/j.jacc.2007.04.074.
29. Slattery M.L., Lundgreen A., Wolff R.K. VEGFA, FLT1, KDR and colorectal cancer: assessment of disease risk, tumor molecular phenotype, and survival. Mol. Carcinog. 2014; 53 (1): E140–50. DOI: 10.1002/mc.22058.
30. Dai X., Chen X., Hakizimana O., Mei Y. Genetic interactions between ANLN and KDR are prognostic for breast cancer survival. Oncol. Rep. 2019; 42 (6): 2255–66. DOI: 10.3892/or.2019.7332.
31. Allegrini G., Coltelli L., Orlandi P., Fontana A., Camerini A., Ferro A., et al. Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. Pharmacogenomics. 2014; 15 (16): 1985–99. DOI: 10.2217/pgs.14.140.
32. Breunis W.B., Davila S., Shimizu C., Oharaseki T., Takahashi K., van Houdt M., et al. Disruption of vascular homeostasis in patients with Kawasaki disease. Involvement of vascular endothelial growth factor and angiopoietins. Arthritis Rheum. 2012; 64 (1): 306–15. DOI: 10.1002/art.33316.
33. Guo H.-F., Kooi C.W.V. Neuropilin functions as an essential cell surface receptor. J. Biol. Chem. 2015; 290: 29 120–6. DOI: 10.1074/jbc.R115.687327.
34. Leung G., Baggott C., West C., Elboim C., Paul S.M., Cooper B.A., et al. Cytokine candidate genes predict the development of secondary lymphedema following breast cancer surgery. Lymphat. Res. Biol. 2014; 12 (1): 10–22. DOI: 10.1089/lrb.2013.0024.
35. Miaskowski C., Dodd M., Paul S.M., West C., Hamolsky D., Abrams G., et al. Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery. PLoS One. 2013; 8 (4): e60164. DOI: 10.1371/journal.pone.0060164.
36. Hosseinpour M., Mashayekhi F., Bidabadi E., Salehi Z. Neuropilin-2 rs849563 gene variations and susceptibility to autism in Iranian population: a case-control study. Metab. Brain Dis. 2017; 32 (5): 1471–4. DOI: 10.1007/s11011-017-0024-2.
37. Mitchell S.F., Parker R. Principles and properties of eukaryotic mRNPs. Mol. Cell. 2014; 54 (4): 547–58. DOI: 10.1016/j.molcel.2014.04.033.
38. Sharma Y., Miladi M., Dukare S., Boulay K., Caudron-Herger M., Groß M., et al. A pan-cancer analysis of synonymous mutations. Nat. Commun. 2019; 10: 2569. DOI: 10.1038/s41467-019-10489-2.
39. Chu D., Wei L. Nonsynonymous, synonymous and nonsense mutations in human cancer-related genes undergo stronger purifying selections than expectation. BMC Cancer. 2019; 19: 359. DOI: 10.1186/s12885-019-5572-x.
40. Borràs N., Orriols G., Batlle J., Pérez-Rodríguez A., Fidalgo T., Martinho P., et al. Unraveling the effect of silent, intronic and missense mutations on vwf splicing: contribution of next generation sequencing in the study of mRNA. Haematologica. 2019; 104: 587–98. DOI: 10.3324/haematol.2018.203166.
41. Dhamijaa S., Menon M.B. Non-coding transcript variants of protein-coding genes – what are they good for? Review. RNA Biol. 2018; 15 (8): 1025–31. DOI: 10.1080/15476286.2018.1511675.
42. Dozmorov M. Disease classification: from phenotypic similarity to integrative genomics and beyond. Brief. Bioinform. 2019; 20 (5): 1769–80.DOI: 10.1093/bib/bby049.
43. Kontou P.I., Pavlopoulou A., Dimou N.L., Pavlopoulos G.A., Bagos P.G. Network analysis of genes and their association with diseases. Gene. 2016; 590 (1): 68–78. DOI: 10.1016/j.gene.2016.05.044.
44. Mi Z., Guo B., Yin Z., Li J., Zheng Z. Disease classification via gene network integrating modules and pathways. R. Soc. Open Sci. 2019; 6 (7):190214. DOI: 10.1098/rsos.190214.